Multiepitope Peptide Vaccination in Melanoma

Phase 2

• Conditions: Metastatic Melanoma

• Registration Number: NCT00153569
• Lead Sponsor: Charite University, Berlin, Germany

Brief Summary

This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients

Detailed Description

Not available

Study Timeline

• Study Start: 2003-03
• Status Verified: 2005-09
• Study Completion: 2005-09
• Study First Submitted: 2005-09-08
• Study First Submitted QC: 2005-09-08
• Study First Posted: 2005-09-12
• Last Update Submitted: 2010-05-25
• Last Update Posted: 2010-05-26

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Metastatic melanoma
• HLA-A1, -A2, -A24, -B44

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Clinical efficacy

Secondary Outcome Measures

Name	Time	Method
Immune response
Safety

Trial Locations

Locations (1)

Hem&Onc Charité CBF; 🇩🇪 Berlin, Germany